Alex Federation
Alex Federation is Co-Founder and CEO at Talus Bioscience. Alex was Lead Bioinformatics Scientist & Pharma Alliance Manager at SEngine Precision Medicine and Senior Data Scientist at Navigating Cancer. Alex was also Founder and Director at University of Rochester Summer Research Experience. Alex held a Research Fellow role at Altius Institute for Biomedical Sciences.
Milad Alucozai spotlights Talus Bio's Ptarmigan-1: a 256-dimensional lookup model that screens trillions of compounds across the regulome and outperforms docking on STAT6 and KRAS G12C
Milad Alucozai describes Talus Bio's Ptarmigan-1, a model that maps proteins and small molecules into a shared 256-dimensional space to enable very fast, large-scale virtual screening across the human regulome without relying on static structures, and reports strong validation on STAT6 and KRAS G12C that suggest the model learned biological signals rather than memorizing data.
GeekWire Awards Health Innovation Finalists Spotlight Cancer-Fighting Biotechs Including Archon Biosciences with $20M AI-Driven Protein Therapy
The GeekWire Awards finalists for Health Innovation of the Year primarily consist of companies developing advanced cancer-fighting technologies, alongside startups improving healthcare management. Notable finalists include Archon Biosciences, which recently secured $20 million to develop AI-optimized protein therapies, Fred Hutch Cancer Center, and others.
Talus Bio names Chris Joyce, MBA as VP of Business Development to drive pharma deals and advance TF therapeutics
Talus Bio hired Chris Joyce, MBA as VP of Business Development to accelerate pharma partnerships and advance its transcription factor therapeutics, including two programs targeting TBXT for non-small cell lung cancer and NONO-related androgen receptor splicing in castration-resistant prostate cancer.
By Alex
Alex Federation says AI drug-discovery models proliferate but lack lab validation, urges third‑party testing
Alex Federation attended an AI drug discovery conference and reports many new models lack experimental lab validation, with most evaluated on the same public datasets; he argues for more third‑party and in‑house lab testing and discusses challenges in choosing small‑molecule targets and success metrics.
Alex Federation: Ptarmigan-1 enables structure-free, hours-long compound screens versus $1M+ months-long co-folding runs for single targets
Alex Federation explains that traditional co-folding models for large-scale drug discovery are computationally intensive and costly (potentially over $1M per target), while Ptarmigan-1 performs structure-free screening to produce testable compounds within hours, enabling faster lab follow-up.
Organizations
See all 8-
Talus Bioscience Executive Officer, Director, Promoter 2024–present, Chief Executive Officer & Co-Founder 2020–present · current
-
SEngine Precision Medicine Lead Bioinformatics Scientist & Pharma Alliance Manager 2020 · past
-
Navigating Cancer Senior Data Scientist 2019–2020 · past
Education
-
Harvard University Ph.D., Chemical Biology · 2011–2015
-
University of Rochester B.S., Chemistry, Cell & Developmental Biology · 2007–2011
Online
Questions about Alex Federation
Who is Alex Federation?
Alex Federation is Chief Executive Officer & Co-Founder at Talus Bioscience.
Which organizations is Alex Federation associated with?
On Seattle Flow, Alex Federation is listed with Talus Bioscience, SEngine Precision Medicine, Navigating Cancer and 5 more.
Where did Alex Federation study?
Alex Federation studied at Harvard University and University of Rochester.
Where is Alex Federation based?
Alex Federation is based in Seattle, Washington, United States.